Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 amp |
| Therapy | Selumetinib |
| Indication/Tumor Type | stomach cancer |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 amp | stomach cancer | resistant | Selumetinib | Preclinical | Actionable | In a preclinical study, Koselugo (selumetinib) did not inhibit growth of gastric cancer cells with FGFR2 amplification in culture (PMID: 19755509). | 19755509 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (19755509) | Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. | Full reference... |